President at Forvest Global Wealth Management
Member since: Mar '08 · 978 Opinions
He and his team spend a lot of time talking to companies. What he's hearing is that there's a better sense that the painful, original, "liberation day" tariffs won't be there. They've had a better chance to respond in terms of diversifying supply chains as well as adjusting prices. The market wants to have it all done in the snap of your fingers, but it all takes time.
It's really a general discomfort with the US. It has been king, with the king dollar, and the US market has been 75% of global markets. Everyone talks about NVDA. Well, NVDA is bigger than most markets around the world with the exception of Japan.
If the bloom comes off the rose, the money will rotate. It's not that the US will be abandoned in total, but money will continue to flow to Europe on one side of the pond and Japan on the other. The notion of the US being the only place to be is falling off.
Yes, that's exactly the reason to own Sprott. It's a diversifier. Gold is a way as an investor to protect yourself from inflation and geopolitical concerns. This name brings leverage to gold because of assets they own and funds they manage. It also brings uranium. He sold some last week to take some profit after an unbelievable run. Dividends go up.
Doesn't see gold or uranium falling. Great place to park your money.
Did everything right, yet down today ~4%. Expectations have been set very high for the traditional growthy and earnings momentum names. If everybody owns the stock, what's your next move? Someone out there didn't like what they saw and hit the sell button, and then it's just investor psychology at work.
He stays home for oil and gas stocks, especially because years of underappreciating Canada has led to lower valuations. For dividends coming from the O&G patch, especially in Canada where they're tax-effective, there's no better place to be. With this name, you're buying the oil price, but he believes more in the gas price.
Worth taking a good, hard look at. Phenomenal yield, and he likes yield. Chart is starting to form a bit of a bottom. Low PE. Has things in the pipeline that the market's not paying for. If you're a longer-term investor, well worth sitting on it and getting rewarded while you wait for an upside pop from the drugs coming through as hoped.
He's looking at it closely.
Tough one. Spun out KVUE, which is in a nice space, but the stock's done nothing. JNJ is now more drugs and medical devices, and its stock's done nothing either. Drug companies are difficult to own, really have to do your homework.
He doesn't want to recommend selling. Drug pipeline sounds good. Good earnings release, and has a bit of earnings momentum behind it. So might not be the time to sell. Yield is ~3%.